Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5’UTR variants in three-generational pedigree
Jakub Trizuljak,
Paulína Likavcová,
Kateřina Staňo Kozubík,
Zuzana Vrzalová,
Jakub Hynšt,
Tereza Deissová,
Jiří Štika,
Lenka Radová,
Marie Prudková,
Jana Vaculová,
Ivona Blaháková,
Petr Smejkal,
Jan Kamelander,
Šárka Pospíšilová,
Michael Doubek
Affiliations
Jakub Trizuljak
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Paulína Likavcová
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Kateřina Staňo Kozubík
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Zuzana Vrzalová
Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic
Jakub Hynšt
Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Tereza Deissová
Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Jiří Štika
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Lenka Radová
Centre of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Marie Prudková
Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic
Jana Vaculová
Department of Clinical Haematology and Haematooncology, Hospital Havířov, Havířov, Czech Republic
Ivona Blaháková
Department of Internal Medicine - Haematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University and ERN EuroBloodNet Centre, Brno, Czech Republic
Petr Smejkal
Department of Clinical Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic
Jan Kamelander
Department of Clinical Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic
Šárka Pospíšilová
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Michael Doubek
Institute of Medical Genetics and Genomics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
Inherited thrombocytopenias (ITs) encompass a group of rare disorders characterized by diminished platelet count. Recent advancements have unveiled various forms of IT, with inherited thrombocytopenia 2 (THC2) emerging as a prevalent subtype associated with germline variants in the critical 5’ untranslated region of the ANKRD26 gene. This region is crucial in regulating the gene expression of ANKRD26, particularly in megakaryocytes. THC2 is an autosomal dominant disorder presenting as mild-to-moderate thrombocytopenia with minimal symptoms, with an increased risk of myeloproliferative malignancies. In our study of a family with suspected IT, three affected individuals harbored the c.-118C>T ANKRD26 variant, while four healthy members carried the c.-140C>G ANKRD26 variant. We performed a functional analysis by studying platelet-specific ANKRD26 gene expression levels using quantitative real-time polymerase-chain reaction. Functional analysis of the c.-118C>T variant showed a significant increase in ANKRD26 expression in affected individuals, supporting its pathogenicity. On the contrary, carriers of the c.-140C>G variant exhibited normal platelet counts and no significant elevation in the ANKRD26 expression, indicating the likely benign nature of this variant. Our findings provide evidence confirming the pathogenicity of the c.-118C>T ANKRD26 variant in THC2 and suggest the likely benign nature of the c.-140C>G variant.